APAC family-office health protocols have converged on weekly semaglutide 2.4mg as the anchor aging intervention for the region's premium concierge medicine market. The SELECT trial (NEJM, November 2023, n=17,604, Novo Nordisk-funded) enrolled adults with existing atherosclerotic cardiovascular disease, showed 20% relative risk reduction on a MACE primary endpoint, and did not enrol a metabolically healthy adult over forty. That population was not in the trial.

The capital read SELECT as a general aging benefit. The clinical read is narrower: a cardiovascular drug in a cardiovascular population delivered a cardiovascular outcome. The FLOW trial (NEJM, May 2024, n=3,533, chronic kidney disease, primary composite renal-cardiovascular endpoint) added organ-protection evidence in a second disease population. Neither study ran a biological aging endpoint. Not Phenotypic Age, not DunedinPACE, not circulating p16INK4a. NMPA's Center for Drug Evaluation approved semaglutide for type 2 diabetes management in January 2021. Neither regulator has moved. At HSA Singapore, semaglutide carries two registered indications: glycaemic control in type 2 diabetes, and chronic weight management in adults with initial BMI of 30 or above. Aging is not listed. The concierge prescribing running across Singapore, Hong Kong, and mainland China's tier-one premium clinics is operating outside both of them.